Sangamo Therapeutics is set to become the first company to test a Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) candidate in humans after the UK’s Medicines Healthcare Products Regulatory Agency gave the trial the go-ahead.
TX200 is being studied for the prevention of immune-mediated rejection following HLA-A2 mismatched kidney transplantation for end-stage renal disease (ESRD).
TX200, which has been developed in collaboration with Professor Megan Levings of the University of British Columbia, entered Sangamo’s pipeline in 2018 as part of the acquisition of TxCell.
Sangamo said it expects to open the first clinical sites for the STEADFAST study in 2020.
“This innovative and personalized cellular therapy approach for HLA-A2 mismatched kidney transplantation is designed to help regulate the body’s immune system specifically and locally to promote acceptance of an immunologically mismatched donor organ,” said Adrian Woolfson, Head of R&D at Sangamo.
“Beyond transplantation, we plan to explore the potential of CAR-Tregs in a range of autoimmune and inflammatory diseases.”